Genmab — September 2015
-
Det er fandme en vild kommentar han slutter af med. Han siger deres prækliniske pipeline er så stærk at de produkter de fører frem vil distancere alt de kender til findes i dag !
-
Super. Tak 89.

-
Angående Xencors CD38/CD3 bispecifikke antistof, så sagde Jan på Post ASH seminaret 2014, at han ikke kunne se det nå i klinikken - og det ville skabe drama, hvis det gjorde. Han havde mailer to af sine top kliniske eksperter der havde pillet ideen ned på få sekunder.
-
-
Jan talte om to nye forsøg med HTF. Her til morgen er der et nyt Phase1 forsøg annonceret. 24 patienter safety. https://www.clinicaltrials.gov/ct2/show/NCT02552121?term=tf-adc&rank=1
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind